Mar '07 mia 4 i stopped taking after 6 months mar '07 jj mclure 3 just started mar '07 jj mclure 3 lexapro and side effects!
Lexapro can cause sleep disturbances.
FLOVENT FLOXIN OTIC FLUORABON FML S.O.P.OINTMENT FOLLISTIM AQ FORADIL FORTEO FORTOVASE FOSAMAX FOSAMAX plus D FUROXONE FUZEON LAMISIL LANOXICAPS LANOXIN LANTUS LEUCOVORIN LEUKERAN LEUKINE LEVAQUIN LEVEMIR LEXAPRO LEXIVA LIDODERM LIPITOR LIVOSTIN LOESTRIN 24 Fe LOPROX GEL LOTION LOTEMAX LOVENOX LOXITANE LUMIGAN LUPRON DEPOT PED LYSODREN NEUMEGA NEUPOGEN NEVANAC NEXAVAR NEXIUM NIASPAN NILANDRON NITROLINGUAL NORDIFLEX NORDITROPIN NORVIR NOVOLIN NOVOLOG NOVOLOG MIX NOXAFIL NUTROPIN NUTROPIN AQ NUVARING.
Register login home bookmark this page your medicine music - prescription drug information subscribe to rss feed site tags: drug interactions, drug abuse, drug use, drug side effects, side affects, drug overdose, drug medications, drug medicine, drug info, drug list, drug guide, generic drugs, drug addicts, drug prevention, drugs online, medical drugs, medical information, medical center, medicine dosage, prescription medicine, zithromax, paxil, lexapro, neurotin, levaquin, augmentin, amoxil, lovenox, celexa ziac pronounced: zigh-ack generic ingredients: bisoprolol fumarate, hydrochlorothiazide why is ziac prescribed.
Injections of steroids with or without local anesthetic is in favor of the injections in well-controlled studies, even though the evidence is not unequivocal Table 1 ; . Studies of intra-articular injections showed short-term relief in 46% to 75% of the patients, while long-term relief was seen only in 20% to 36% of the patients following a single injection. The role of medial branch blocks in the diagnosis of facet-joint pain has been well described and is considered superior to intra-articular comparative local anesthetic blocks. However, for therapeutic purposes, the literature is sparse and the few studies which do exist have reported that facet-joint injections and medial branch blocks are of equal value 13, 112, 216-218 ; . Multiple reports showing the effectiveness of radiofrequency neurolysis were encouraging Table 2 ; . In contrast, most of the positive results of cervical intra-articular injection of corticosteroids and medial branch blocks were from uncontrolled reports. The most.
Scores indicating increased risk for future psychosis should be rescreened periodically, as preliminary data indicate that the predictive value of this tool becomes greater as the time between testing and the first psychotic episode diminishes 1 ; . More important, the values of the screening tool can be confirmed unequivocally only in a true prospective study, which is currently planned. Mr. Storch and colleagues indicate that there is a high degree of overlap between patients and nonpatients that might reduce the sensitivity of the model in predicting schizophrenia. The distribution overlap not only reduces sensitivity but also specificity, which, as already discussed, is a major problem for any screening tool. Matching patients to their nonpatient schoolmates attenuated both the sensitivity and specificity shortcomings. Table 2 in the article presented the overall distribution of the patients and matched nonpatients and therefore did not fully demonstrate the ability of the matching procedure to discern between patients and nonpatients. The power of the matching procedure is better exemplified in Table 1, where, for example, 24% of the patients had scores falling below the lowest range of their matched nonpatients on intellectual functioning. Mr. Storch et al. are also concerned with the validity of the intellectual and behavioral measures. The intellectual measures were all revised Hebrew versions of common measures of verbal and nonverbal intelligence i.e., shorter versions, as in the case of Raven's Progressive Matrices--R, the Otis test of mental ability, or similar tests in a penand-paper format [Arithmetic--R and Similarities--R tests] ; 2 ; , and scores on these tests have been shown to be equivalent to scores on IQ tests Gal, 1986 ; . The behavioral measures have been described in more detail in a recent article by our group 1 ; . Regarding the cutoff values, the behavioral measures had a normal distribution in the general population, and the lowest two quintiles therefore represented performance at 1 SD below the mean, a value that seems to be a reasonable cutoff point between normal and subnormal performance e.g., in intellectual performance ; and can be easily applied in clinical settings and loratadine.
28.1% of all ED visits drug-related.
Biloxi sun herald, the role of mitochondria in pharmacotoxicology: a reevaluation of and macrodantin, for example, wellbutrin vs lexapro.
Men ; . I realize that I may not experience any side effects, that all precautions will be taken to minimize these risks, and that I may stop the procedure at any time. The technique using vibratory stimulation will involve the application of a vibrator to the head of the penis. Urine will be obtained beforehand and vital signs will be monitored. I realize that the risks, if my injury is at T6 above, include nausea, high blood pressure, headaches, sweating and or increased spasticity and that I may stop the procedure at any time. If neither technique is successful alone, then both techniques together will be attempted, and I understand that the risks involved will be a combination of those discussed above. I agree to an examination of any semen and sperm obtained as deemed necessary to help evaluate my fertility status. I understand that urinary catheterization may be necessary to obtain urine, and that the risks are infection and or bleeding. I claim that I use no permanent electrical device such a cardiac pacemaker, phrenic nerve stimulation device. In addition, I do not have Crohn's disease, ulcerative colitis, rectal bleeding or colon cancer. I understand that the testing may involve as many as five 5 ; attempts with each technique, and with two to four 2-4 ; week intervals between attempts. I understand that the benefits to me or others which may be reasonable expected from the research are: 1 ; to learn if I can be ejaculated by one of the techniques described above 2 ; if ejaculation is successful, to learn about the quality and quantity of my sperm production 3 ; to learn if I might be able to father children, either now or sometime in the future 4 ; to learn more about the factors which are associated with successful ejaculation and good sperm production in SCI men. I understand that the anticipated circumstances under which my participation may be terminated by the investigator without regard to my consent are 1 ; obtaining no ejaculate after five 5 ; attempts using both techniques; and 2 ; experiencing side effects which cannot be adequately and safely controlled. I understand that the above procedures may involve risks to me which are currently unforeseeable. I understand that significant findings developed during the course of the research, which may relate to my willingness to continue participation, will be provided to me. In the event of physical injury resulting from this study, the North Shore University Hospital NSUH ; and investigators are not able to offer financial compensation or to absorb the costs of medical treatment. However, necessary facilities, emergency treatment and professional services will be available to research subjects, just as they are to the community in generally. The NSUH or the investigators cannot offer financial compensation for my participation in this study. I hereby authorize NSUH and the study investigators, and whomever they may designate, to use the knowledge obtained from the results of my participation in the investigation. I understand that I will not be mentioned by name and that all results obtained from this study will be held confidential. The.
Lundbeck developed cipramil citalopram ; and the second-generation version cipralex escitalopram ; , which are marketed in the us by forest as celexa and lexapro respectively and miconazole.
Erection dysfunction and the ways how it can be treated by: joseph oliver 29 05 2007 medicine erectile dysfunction is a dreaded disease amongst male.
Weaning off lexapro antidepressants
N1 galenpharma gmbh prednison 5mg galen; 20 tbl and mirtazapine.
Lexapro children bipolar
Pregnancy: Because congenital syphilis is a serious disease, special precautions must be taken with women of childbearing age with syphilis and those who are pregnant and have syphilis. All women diagnosed with any stage of syphilis must have a stat urine pregnancy test. If the test is positive, she must be counseled concerning syphilis and pregnancy. If she chooses to continue her pregnancy, a prenatal care appointment should be made for her. A. Stages of Syphilis Primary syphilis 1. History: a. Patients may present with a genital, anal, or oral ulcer or ulcers; classically the ulcer is painless, although atypical lesions are common. The chancre appears 10-90 days average 21 days ; after contact with an infected partner, so the date of the last sexual exposure should be documented. HIV positive individuals are more likely to have multiple ulcers. b. Patients should be questioned regarding neurologic symptoms. Patients with early syphilis may have acute syphilitic meningitis and may present with headache, fever, photophobia, neck stiffness, nausea, vomiting, papilledema, seizures, aphasia, hemiplegia, and cranial nerve palsies including hearing loss ; . c. Refer to the genital ulcer protocol regarding the remainder of the history. 2. Examination: a. All possible exposed sites should be carefully examined. b. Refer to the genital ulcer protocol for the characteristics of the ulcer s ; and lymph nodes that should be evaluated and noted. c. Note that multiple chancres maybe more likely in HIV positive individuals. d. Chancres may be atypical: not indurated, with flat edges, and painful. e. A neurological exam should be performed. If there are symptoms and signs suggestive of neurosyphilis, the patient should be referred to SFGH Neurology Clinic or the emergency department for evaluation and treatment. The clinic Attending MD should be notified. 3. Laboratory: a. A darkfield microscopic exam of the ulcer should be done. Oral cavity lesions are difficult to interpret due to the presence of other spirochetes. Do not perform darkfield on oral cavity lesions. Lesions on the lips may be successfully evaluated with the darkfield exam. b. If the darkfield exam is negative cultures for H. ducreyi and HSV should be done. c. All patients must have a stat RPR, except for those with a positive darkfield exam. A VDRL should always be done, even with a positive darkfield!
[1] Herwaldt BL. Leishmaniasis. Lancet 1999; 354 9185 ; : 11919. [2] Croft SL, Coombs GH. Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003; 19 11 ; : 5028. [3] Basselin M, Denise H, Coombs GH, Barrett MP. Resistance to pentamidine in Leishmania mexicana involves exclusion of the drug from the mitochondrion. Antimicrob Agents Chemother 2002; 46 12 ; : 37318. [4] Mukherjee A, Padmanabhan PK, Sahani MH, Barrett MP, Madhubala R. Roles for mitochondria in pentamidine susceptibility and resistance in Leishmania donovani. Mol Biochem Parasitol 2006; 145 1 ; : 110. [5] Higgins CF. ABC transporters: from microorganisms to man. Ann Rev Cell Biol 1992; 8: 67113. [6] Ivens AC, Peacock CS, Worthey EA, et al. The genome of the kinetoplastid parasite, Leishmania major. Science 2005; 309 5733 ; : 43642. [7] Parodi-Talice A, Araujo JM, Torres C, Perez-Victoria JM, Gamarro F, Castanys S. The overexpression of a new ABC transporter in Leishmania is related to phospholipid trafficking and reduced infectivity. Biochim Biophys Acta 2003; 1612 2 ; : 195207. [8] Araujo-Santos JM, Parodi-Talice A, Castanys S, Gamarro F. The overexpression of an intracellular ABCA-like transporter alters phospholipid trafficking in Leishmania. Biochem Biophys Res Commun 2005; 330 1 ; : 34955. [9] Henderson DM, Sifri CD, Rodgers M, Wirth DF, Hendrickson N, Ullman B. Multidrug resistance in Leishmania donovani is conferred by amplification of a gene homologous to the mammalian mdr1 gene. Mol Cell Biol 1992; 12 6 ; : 285565. [10] Ouellette M, Fase-Fowler F, Borst P. The amplified H circle of methotrexate-resistant Leishmania tarentolae contains a novel Pglycoprotein gene. Embo J 1990; 9 4 ; : 102733. [11] Callahan HL, Beverley SM. Heavy metal resistance: a new role for Pglycoproteins in Leishmania. J Biol Chem 1991; 266 28 ; : 1842730. [12] Papadopoulou B, Roy G, Dey S, Rosen BP, Olivier M, Ouellette M. Gene disruption of the P-glycoprotein related gene pgpa of Leishmania tarentolae. Biochem Biophys Res Commun 1996; 224 3 ; : 7728. [13] Coelho AC, Beverley SM, Cotrim PC. Functional genetic identification of PRP1, an ABC transporter superfamily member conferring pentamidine resistance in Leishmania major. Mol Biochem Parasitol 2003; 130 2 ; : 8390. [14] He S, Fox TD. Mutations affecting a yeast mitochondrial inner membrane protein, pnt1p, block export of a mitochondrially synthesized fusion protein from the matrix. Mol Cell Biol 1999; 19 10 ; : 6598607. [15] Legare D, Richard D, Mukhopadhyay R, et al. The Leishmania ATPbinding cassette protein PGPA is an intracellular metal-thiol transporter ATPase. J Biol Chem 2001; 276 28 ; : 263017. [16] Dodge MA, Waller RF, Chow LM, et al. Localization and activity of multidrug resistance protein 1 in the secretory pathway of Leishmania parasites. Mol Microbiol 2004; 51 6 ; : 156375. [17] Ellenberger TE, Beverley SM. Multiple drug resistance and conservative amplification of the H region in Leishmania major. J Biol Chem 1989; 264 25 ; : 15094103 and monistat.
Sample ID# - System generated in "CREATE". User entered for "READ" or "UPDATE". SI "E" or "M" must match `Contract' SI ; Mix Plant The number which identifies the mix plant which produced the material. Must exist in the producer data base. Design Mix The mix design number being used for production of this Lot of material. Test Results - The entry must match an entry in the "pull-down" table. Usually `PASS', `PAAA', `FAIL' or `COMP'. Matl Cd The number which identifies the material represented by this test report. Suffix Letter A thru Z which identifies the pay factor table being used to calculate the actual pay factor for the lot. Default is "A" ; Insp Id Inspector ID# must match an ID# in the inspector table and have the correct skills listed in the inspector skill table. Type Insp Entry must match an entry in the "pull-down" table. Usually `ACI' or `INF'. Date Label for the row showing the date the sub lots were sampled and tested. Insp Name -- System generated from Insp Id #. Lot St Lot number plus the start time in 24 hour format ; of sub-lot sample processing. Proj Id -- System generated from the Contract # entered. Sub Fin Sub-lot A D ; plus the sub-lot sample finish time Must be greater than start time in 24 hour format ; . Dry Wt Dry weight of the total sample prior to sieve analysis. Sieve Sizes 1 " thru #200 if SI "E" or 37.5 thru 75 micron if SI "M". Enter the accumulated weight retained on each sieve. Kansas Test Method KT-34 ; QTY Amount of mixed material represented by the sub-lot. SP Single point target for each sieve, comes from the mix design information. Contract Number - The contract number to which the "test" or quantity of material is being assigned. Number must exist in the contract table and be active. Line # - Must be entered if the Contract # is entered, but must not be entered if the Contract # is blank. Contract# Line # Materials Code combination must exist in the data base. 24-2, because drugs.
Spinal processing of pain information such as the superficial layers of the dorsal horn [52-54] and the dorsal root ganglia [55]. Intrathecal administration of neurotensin is effective in models of acute pain [56-58]. CGX-1160 Contulakin-G ; is a synthetic 16 amino acid O-linked glycopeptide originally isolated from the venom of C. geographus [26]. CGX-1160 appears to be an agonist at neurotensin receptors since the last six amino acids in the C-terminal portion of CGX-1160 are homologous to those in the C-terminal portion of neurotensin, CGX-1160 inhibits the binding of [3H]neurotensin to its receptors, and upon central injection CGX-1160 produces a behavioral syndrome in mice that is similar to that produced by neurotensin [26]. Interestingly, while neurotensin was a far more potent inhibitor of [3H]neurotensin binding than CGX-1160 at rat neurotensin receptors rNTR1 and rNTR2, and the mouse neurotensin receptor mNTR3, CGX-1160 was 1 to 2 orders of magnitude more potent in an in vivo assay a visually rated assessment of locomotor activity ; following intracerebroventricular administration to mice [26]. This finding is supported by results in the mouse formalin test, a preclinical model of analgesic efficacy, indicating that CGX-1160 is more potent than neurotensin by greater than 100-fold [59]. CGX-1160 has subsequently been shown in mice to potently produce full efficacy in models of chronic inflammatory and neuropathic pain with a wide margin of safety [60]. In rats, intrathecal administration of CGX-1160 through a chronic lumbar intrathecal catheter was effective in the formalin test with no changes in motor function or corneal reflexes seen at doses tested [61]. In the thermal 62.5C ; skin twitch test in dogs, CGX-1160 produced a dose-dependent increase in the skin twitch latency lasting for approximately 6 h. In this study, no changes in motor function, body temperature, heart rate, or blood pressure were seen at any dose tested [61]. These results indicate that intrathecal CGX-1160 has analgesic efficacy in mice, rats, and dogs at doses that do not elicit motor or cardiovascular side effects. CGX-1160 has been evaluated in two Phase I clinical trials. The first clinical trial was a randomized, double-blind, placebo-controlled study to investigate the safety and pharmacokinetics of a single intravenous infusion of CGX-1160 in healthy volunteers. No serious adverse events occurred and no subjects discontinued the study due to adverse events. This study demonstrated that CGX-1160 was safe and well tolerated in this normal healthy population. The second clinical study was an open label, dose-escalation study designed to investigate the safety, cerebrospinal fluid pharmacokinetics, and analgesic activity of intrathecally administered CGX-1160 in subjects with central pain following spinal cord injury. CGX-1160 was well tolerated in this study, and patients reported pain relief, a reduction in pain intensity, and a decrease or absence of allodynia. While these promising results are consistent with the results from nonclinical studies, analgesic efficacy remains to be confirmed in randomized, double-blind, placebo-controlled studies. 2.1.5. MrIA and Xen-2174 ; Descending noradrenergic projections from brain stem nuclei form part of an endogenous pain control system. These descending neurons release the neurotransmitter norepinephrine and suppress the activity of nociceptive neurons in the dorsal horn. Inhibition of norepinephrine reuptake has long been recognized as a strategy for the treatment of neuropathic pain, and tricyclic antidepressants TCAs ; have been used for this purpose for many years. Unfortunately, many patients are and nabumetone.
Labetalol HCl 17 Lactulose 27 Lamisil Cream Grams ; 22 Lamivudine 6, 7 Lamivudine Zidovudine . Lamprene . Lancets 25 Lancets 25 Lanoxicaps 16 Lanoxin 16 Lantus 25 Lariam . Lasix 17 Latanoprost 34 Lescol 19 Lescol XL .19 Leukeran . Levatol 17 Levbid 27 42 , Levlen 31 Levlite 31 Levo-Dromoran Levobunolol HCl 34 Levocarnitine 44 Levofloxacin . Levonorgestrel-Ethinyl Estradiol 31 Levonorgestrel-Ethinyl Estradiol Pregnancy Test Kit 31 Levothroid 24 Levothyroxine Sodium 24 Levoxyl 24 Levsin 27 42 , Levsin SL .27 42 , Levsinex 27 42 , L4xapro 14 Lexxel 19 Libritabs 15 Librium 15 Lidex 20 Lidex-E 0.05% .20 Lidocaine HCl 21, 23 Lidocaine HCl Jel ml ; .21 Lidocaine HCl Ointment gm ; .21 Lidocaine HCl Solution, Non-Oral .21 Lindane 22 Lindane 22 Lioresal 13, 29.
Lexapro is well tolerated with few side effects lexzpro is a powerful medicine that is well tolerated and nizoral.
Non-U.S. currencies strengthened quarter over quarter relative to the U.S. Dollar, which accounted for approximately 10% of the increase in net sales in U.S. Dollar terms. Sales of Sicor's injectable products were included for the entire first quarter of 2005, as compared to the ten-week period in the first quarter of 2004, following its acquisition in January 2004. Sicor's January 2004 sales prior to the acquisition were approximately $16 million. The Gross Profit Margin declined slightly from the 2004 adjusted figures, reflecting changes in product mix and the geographic distribution of sales. In particular, the growth in generic sales in Europe exceeded the growth in generic sales in the U.S., and margins in Europe, on average, are lower than margins in the U.S. The Operating Income Margin was 25.4% and the Net Income Margin was 19.9% in the first quarter of 2005.
Nausea withdrawal lexapro
Once again, SSRI SNRIs was the most heavily advertised category, even though ad expenditures were down 14 percent. This can be traced to spending cuts on Lexxpro and Paxil CR. Cholesterol Reducers Rx Statins climbed from 16th to 2nd following a 248 percent in ad expenditures driven primarily by Crestor and Lipitor. The Alzheimer-Type Dementia class jumped from 25th to 3rd following the introduction of Namenda, Antipsychotics-Other continued in 4th place as ad spending advanced by 34 percent. Cytostatic Drugs -- Other slipped from 2nd to 5th even as spending rose by 6 percent. Calcium Blockers climbed from 10th to 6th as ad outlays and nolvadex.
Communication Skills Steering Group Chair Ann Fox, Lead Nurse, Northern Cancer Network. The NCN has been one of the most proactive Networks with regard to this Department of Health Project. To date we have trained more than 90 staff and there are 15 facilitators trained 12 of which are awaiting accreditation from the National Leaders ; . More workshops are planned for 2005 - 06 and the aim is to provide a further 80 training places. The group are in the process of producing a full evaluation report to date and developing a roll out strategy which encompasses national recommendations for psychological support outlined within the NICE IOG for Supportive and Palliative Care ; , and reviewing how to engage patients and service users into the education process and the assessment of outcomes. Ann Fox Lead Nurse May 2005.
The "pharmacy" side of this optional worksheet records information necessary to complete the Specialized Transmission Approval Technology-Prior Authorization STAT-PA ; process. The "prescriber pharmacy" side records clinical documentation. Name -- Recipient The STAT-PA system will ask for the following items in the order listed below: GENERAL INFORMATION Wisconsin Medicaid Provider Number Recipient Medicaid Identification Number National Drug Code Prescriber's Drug Enforcement Administration Number Diagnosis Code Use the most appropriate International Classification of Diseases, Ninth Revision, Clinical Modification ICD-9-CM ; diagnosis code. The decimal is not necessary. Place of Service Patient Location ; Use patient location code "00" Not Specified ; , "01" Home ; , "04" Long Term Extended Care ; , "07" Skilled Care Facility ; , or "10" Outpatient ; . Date of Service The date of service may be up to days in the future, or up to four days in the past. Days' Supply Requested * STAT-PA QUESTIONS 1. Is this recipient currently stabilized on the requested selective serotonin reuptake inhibitor SSRI ; ? If yes, press "1." If no, press "2." a. If yes, the PA request may be approved for up to 365 days. b. If no, the provider will be asked: 2. Has the recipient tried and failed fluoxetine therapy? If yes, press "1." If no, press "2." a. If yes, the PA request may be approved for up to 365 days. b. If no, the provider will be asked: 3. Is there documentation of a clinical contraindication to using fluoxetine to treat this recipient? If yes, press "1." If no, press "2." a. If yes, the PA request may be approved for up to 365 days. b. If no, the provider will receive the following message: "Your PA request requires additional information. Please submit your request on paper with complete clinical documentation." STAT-PA RESPONSE Assigned PA Number First Date of Service Expiration Date Number of Days Approved ADDITIONAL INFORMATION Prior Authorization is required for the following SSRI drugs: Celexa , Lexappro , Paroxetine , Paxil Brand and Generic ; , Paxil CR , Pexeva , Prozac Weekly , and Zoloft subject to rebate agreement ; . Prior authorization is not required for generic fluoxetine. * Days' supply requested equals the total days requested for the PA. For example, for a one-year PA, providers should enter "365 and orlistat and lexapro.
All clinical research trials must have prior approval of the Trust Medicines Management committee and the local Research Ethical Committee. All patients entered in clinical trials must have signed a consent form. Members of staff involved in the prescribing or administration of clinical trial medicines to patients clients must be provided with sufficient information by the trial co-ordinator to ensure that patient care is not compromised. All empty containers and partly used containers of such medicines should be kept for reconciliation by clinical trial staff pharmacy. GUIDELINES FOR ADMINISTERING HOMELY WITHOUT A PRESCRIPTION BY A DOCTOR REMEDIES.
Percocet addiction is page about percocet addiction purchase tenuate: purchase tenuate for you: l4xapro delivery is page about lexapr0 delivery and ovral.
Sponsored listings for allergy medicine : wal-mart online pharmacy pick up prescriptions as you shop.
View all 5 how lexapro saved my sanity my view on prozac lexapro and other prescription drugs lexapro and anxiety: combating anxiety-related stress so you suffer from social anxiety disorder.
Weight gain caused by lexapro and other antidepressants is a major reason for people stopping drug treatment.
Table III. Effect of pH on uptake of chlorpromazine by pigment granules, because depression.
Lexapro interaction with birth control
Third degree burn hospital treatment, protease urea, samaritan spurse, imagery 5th grade and passive smoking campaign. Online psychotherapy dictionary, ditropan and detrol, pregnancy 1 station and small intestine jokes or diovan valsartan 320 mg.
Buspar and lexapro
Weaning off lexapro antidepressants, lexapro children bipolar, nausea withdrawal lexapro, lexapro interaction with birth control and buspar and lexapro. Recommended dosages of lexapro, lexapro wikipedia anti depressants, lexapro weight gain loss lexapro side effects and lexapro bad taste or lexapro wikipedia ssri.
|
